Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Bluebird Bio Rebrands as Genetix Biotherapeutics, Focusing on Gene Therapy Commercialization

In a significant development for the gene therapy sector, bluebird bio has unveiled its new identity as Genetix Biotherapeutics. This rebranding comes on the heels of the company's recent acquisition by private equity firms Carlyle and SK Capital, marking a strategic shift towards commercial execution in the field of genetic therapies.

NoahAI News9/19/2025

Novo Nordisk Advances in Obesity Treatment with Oral Wegovy, Outperforms Lilly's Trulicity in Diabetes Study

Novo Nordisk has made significant strides in the competitive GLP-1 market, unveiling promising data for its oral formulation of Wegovy and demonstrating superior cardiovascular outcomes for Ozempic compared to Eli Lilly's Trulicity. These developments come at a crucial time as the pharmaceutical giant seeks to maintain its edge in the rapidly evolving obesity and diabetes treatment landscape.

NoahAI News9/19/2025

Startup MoldCo Secures $8M Seed Funding to Revolutionize Mold-Related Illness Treatment

MoldCo, a pioneering virtual clinic addressing mold toxicity, has successfully raised $8 million in seed funding to scale up its innovative approach to diagnosing and treating mold-related illnesses. The funding round, co-led by Cantos and Collaborative Fund, brings the startup's total funding to $11 million since its launch in 2023.

NoahAI News9/19/2025

MilliporeSigma Expands Global Manufacturing with €150M Filtration Plant in Ireland

MilliporeSigma, a subsidiary of Germany's Merck KGaA, has unveiled a state-of-the-art filtration products facility in Cork, Ireland, marking a significant milestone in the company's global expansion strategy. The €150 million ($177 million) investment is part of a larger €440 million ($521 million) commitment to bolster operations in Ireland, announced in May 2022.

NoahAI News9/19/2025

Pfizer and Arvinas Shift Strategy on PROTAC Inhibitor, Seek Third-Party Commercialization

Pfizer and Arvinas have announced a significant change in their approach to the commercialization of vepdegestrant, their jointly developed oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader. The companies have decided to out-license the commercialization rights to a third party, despite having submitted the drug to the FDA for approval just last month.

NoahAI News9/19/2025

QL Biopharm's Once-Monthly GLP-1 Candidate Shows Promise in Phase 2 Weight Loss Trial

Beijing-based QL Biopharmaceutical has unveiled promising phase 2 data for its once-monthly GLP-1 receptor agonist, zovaglutide (ZT002), demonstrating weight loss efficacy potentially rivaling weekly treatments from industry giants Eli Lilly and Novo Nordisk. The results mark a significant step forward in the development of ultra-long-acting obesity treatments, potentially offering patients a more convenient dosing regimen without compromising effectiveness.

NoahAI News9/19/2025

Fujifilm and argenx Expand Partnership, Bringing Vyvgart Production to US Amid Industry Shifts

Fujifilm Biotechnologies and argenx have announced a significant expansion of their manufacturing partnership, signaling a major shift in pharmaceutical production strategies. This move comes as the industry grapples with potential sector-specific tariffs and an increasing focus on domestic manufacturing capabilities.

NoahAI News9/19/2025

GE HealthCare Considers Stake Sale in China Division Amid Market Challenges

GE HealthCare, a leading player in the global medical technology industry, is reportedly exploring options for a potential stake sale in its China division. This strategic move comes as the company navigates a complex landscape of market challenges, including recent declines in revenue and ongoing geopolitical tensions affecting international trade.

NoahAI News9/19/2025

Genentech Announces Leadership Changes in Marketing and Pipeline Development

Genentech, a member of the Roche Group, has unveiled significant changes in its leadership structure, marking a new chapter in the company's marketing and pipeline development strategies. These shifts underscore the pharmaceutical giant's commitment to innovation and strategic growth in key therapeutic areas.

NoahAI News9/19/2025

Akeso's Rise Signals China's Biotech Boom and Global Ambitions

Akeso, a Chinese biotech company founded just 13 years ago with a modest $3 million investment, has emerged as a symbol of China's rapidly evolving pharmaceutical landscape. The company's journey from a small team of researchers to a $15 billion industry powerhouse underscores the dramatic transformation of China's biotech sector and its growing influence on the global stage.

NoahAI News9/17/2025

Sarepta's Elevidys Continues to be Prescribed Despite Safety Concerns

Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, remains in use despite recent safety concerns, according to a new analyst survey. The therapy, which has been subject to regulatory scrutiny following patient deaths, still maintains support from prescribing physicians, particularly for ambulatory patients.

NoahAI News9/17/2025

Novo Nordisk's Cagrilintide Shows Promise in Phase III Obesity Trial

Novo Nordisk has reported encouraging results from a sub-analysis of its Phase III REDEFINE 1 trial, evaluating the long-acting amylin analog cagrilintide as a monotherapy for weight loss. The data, presented at the European Association for the Study of Diabetes (EASD) congress, demonstrates significant weight reduction and improved safety profiles, potentially positioning cagrilintide as a strong contender in the competitive obesity treatment market.

NoahAI News9/17/2025

«1...55 56 57...67 »